Compound from Centella asiatica Stops Drug-Resistant Bacteria in Lab Tests

Antimicrobial resistance is one of the most stubborn health challenges of the decade, contributing to more than a million deaths a year. A new study highlighted by ScienceDaily in April 2026 suggests an unexpected ally: madecassic acid, a triterpenoid compound extracted from Centella asiatica, the herb known in traditional Asian medicine as gotu kola.

In laboratory experiments, madecassic acid disrupted multiple drug-resistant bacterial strains by interfering with virulence pathways and biofilm formation rather than killing bacteria outright. That mechanism is intriguing because it could reduce selection pressure for further resistance — bacteria are less likely to evolve around a drug that disarms them rather than kills them.

“A new study highlighted by ScienceDaily in April 2026 suggests an unexpected ally: madecassic acid, a triterpenoid compound extracted from Centella asiatica, the herb known in traditional Asian medicine as gotu kola.”

The plant has been used for centuries in India, China and Southeast Asia for wound healing and skin conditions; modern science is now isolating its active molecules. The April work adds to a growing pipeline of plant-derived compounds being repurposed for stubborn infections, including methicillin-resistant Staphylococcus aureus (MRSA) and gram-negative pathogens that resist most modern antibiotics.

Researchers stress that animal studies and clinical trials are required before madecassic acid can be developed into a medicine. Still, in a field where breakthroughs are rare, finding a hopeful lead in a humble traditional herb is a quiet but meaningful piece of good news for global health.